Summary & Overview
HCPCS J7205: Factor VIII Fc Fusion Protein Injection, per IU
HCPCS Level II code J7205 designates an injectable recombinant factor VIII Fc fusion protein, reported per international unit for use in patients with hemophilia A. This code identifies a specialty biologic therapy used in replacement and prophylactic regimens to prevent and control bleeding, with implications for drug utilization, prior authorization workflows, and site-of-care cost differences across the U.S.
Key payers in this national overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an explanation of what the code represents, typical sites of service (infusion centers and outpatient settings), and the clinical context for its use. The analysis highlights payer coverage patterns, common billing and documentation considerations, and benchmark metrics where available. Policy-relevant topics include utilization management, specialty drug billing practices, and implications for outpatient versus inpatient administration.
This summary equips billing managers, revenue cycle professionals, and policy analysts with a concise reference to the code's clinical purpose, payer landscape, and the types of benchmarking and policy updates to expect in the full publication. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J7205 represents an injection of factor VIII Fc fusion protein (recombinant), billed per international unit (IU). This product is a recombinant coagulation factor used for replacement therapy in patients with hemophilia A to prevent or control bleeding.
Service type: Therapeutic injectable - clotting factor replacement
Typical site of service: Infusion center, hospital outpatient department, or outpatient clinic
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 28-year-old male with severe hemophilia A presents to the outpatient infusion center for routine replacement therapy. He has a history of recurrent joint bleeds and is on prophylactic recombinant factor VIII Fc-fusion protein therapy dosed by international units (IU). The infusion visit workflow includes verification of the physician order for J7205 (injection, factor VIII Fc fusion protein, recombinant, per IU), patient identity and weight confirmation, review of recent factor trough levels and inhibitor testing, preparation and reconstitution of the product by pharmacy or trained infusion staff, administration via peripheral intravenous bolus or short infusion, vital sign monitoring during and after administration, documentation of lot number and quantity administered (IU), and billing using the per-IU HCPCS code J7205. Typical sites of service are outpatient infusion centers, hospital outpatient departments, or skilled nursing facilities for patients requiring assisted administration. The patient scenario may include prophylactic dosing prior to a high-risk activity, on-demand treatment for an acute joint bleed, or perioperative dosing for minor procedures.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Used when no other applicable modifier from this list applies |